As of 2:31 PM on the 29th, Celltrion Healthcare is trading at 144,400 KRW, down 3.22% from the previous day. The trading volume is 1,210,579 shares, which is 67.03% of the previous day's volume. Celltrion Healthcare is known as the exclusive distributor of Celltrion's biosimilars.


On January 29, Hana Financial Investment researcher Sun Min-jung stated, "A decline in Truxima sales to the US is expected in 2021. However, sales estimates for new products could exceed expectations, so Celltrion Healthcare's estimates may be significantly revised upward after quarterly earnings announcements. Additionally, if the COVID-19 treatment Regkirona receives EUA approval from the US FDA, high growth similar to 2020 is expected to continue in 2021." She set the target price for Celltrion Healthcare at 175,000 KRW.


Over the past five days, individual investors have net sold 108,211 shares of Celltrion Healthcare, while foreigners and institutions have net bought 178,509 shares and net sold 61,635 shares, respectively.


Hot Picks Today

"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ① "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①

※ Source: AI Investment Assistant AI Rassiro


※ This article was generated in real-time by an article automation algorithm jointly developed by Asia Economy and financial AI specialist Thinkpool.


한글 기사 보기
This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing